Sublingual immunotherapy is a first line allergy treatment throughout Europe (in France nearly 90% of immunotherapy patients are on drops, not shots). In the U.S., this convenient form of treatment has not gained as much traction until recently, with the FDA approval of sublingual tablets and increasing clinical data surrounding efficacy and safety. Curex is the first company to introduce this off-label form of sublingual immunotherapy treatment to the U.S. market on a national scale via telemedicine.

Reference

-Sublingual immunotherapy: World Allergy Organization Position Paper 2013 Update

Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal 2014; 7:6 (28 March). doi:10.1186/1939-4551-7-6

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983904/


Did this answer your question?